Financial
FY2025 revenue $6.07bn (+11.5%); operating margin 20.8%; net income $1.06bn.
Cash $3.00bn; debt $600.0m.
Edwards Lifesciences
HQ United States · North America
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Strong
Customer rating
No reviews yet
Financial health
Band: StrongListed: EW
FY2025 revenue $6.07bn (+11.5%); operating margin 20.8%; net income $1.06bn.
Cash $3.00bn; debt $600.0m.
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | US$6.1bn | +11.5% | US$1.3bn | US$1.1bn | Edwards Lifesciences |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
Jan 2026: A US federal court granted the FTC an injunction blocking Edwards' planned acquisition of JenaValve, and Edwards abandoned the deal; the company said it disagreed with the decision.
Cyber & information governance
No company-confirmed or reputably reported data breaches, cyber incidents or regulator actions involving Edwards Lifesciences found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
Jul 2025: Edwards recalled OptiSite and certain femoral arterial cannulae after wire was found exposed at the cannula tip; FDA classed it as the most serious recall type. No serious injuries or deaths had been reported as of May 2025.
Contract performance
No contract terminations, customer disputes or significant NHS contract news involving Edwards Lifesciences found in HSH's search of the last 24 months.
Competitors
No competitors linked yet.